R&D | June 10, 2026
FDA greenlights Lilly’s EBGLYSS for ultra-low-frequency dosing in eczema breakthrough
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
The company announced positive topline data from the Phase 3 ADorable-1 trial
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Subscribe To Our Newsletter & Stay Updated
